CB2 Insights Technology Platform Selected by Dharma Pharmaceuticals to Study Real-World Health Outcomes

CB2 Insights (CSE:CBII; OTCQB: CBIIF), has been selected by Dharma Pharmaceuticals (“Dharma”), as a preferred partner and platform to establish and generate real-world evidence (RWE)…

CB2 Insights (CSE:CBII; OTCQB: CBIIF), has been selected by Dharma Pharmaceuticals (“Dharma”), as a preferred partner and platform to establish and generate real-world evidence (RWE) on a full suite of Dharma products in Virginia. The announcement comes ahead of Dharma’s commencement of sales of high-quality medical cannabis oils to patients in the near future. Dharma’s […]

The post CB2 Insights Technology Platform Selected by Dharma Pharmaceuticals to Study Real-World Health Outcomes appeared first on Technical420.

Leave a Reply

Your email address will not be published. Required fields are marked *